Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to “Hold” at Canaccord Genuity Group

Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a hold rating in a research note published on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on the stock. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Wells Fargo & Company reduced their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Bank of America reaffirmed an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,052.90.

Regeneron Pharmaceuticals Trading Up 2.1 %

NASDAQ:REGN opened at $740.01 on Tuesday. The firm has a 50-day simple moving average of $839.04 and a 200-day simple moving average of $1,000.86. Regeneron Pharmaceuticals has a one year low of $721.08 and a one year high of $1,211.20. The firm has a market cap of $81.32 billion, a P/E ratio of 18.31, a P/E/G ratio of 2.19 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. &PARTNERS acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at $627,000. Cornerstone Wealth Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 2.9% in the 2nd quarter. Cornerstone Wealth Group LLC now owns 3,718 shares of the biopharmaceutical company’s stock valued at $3,908,000 after buying an additional 104 shares during the period. Catalina Capital Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 20.8% in the second quarter. Catalina Capital Group LLC now owns 302 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 52 shares during the last quarter. Premier Path Wealth Partners LLC grew its holdings in Regeneron Pharmaceuticals by 11.1% during the second quarter. Premier Path Wealth Partners LLC now owns 620 shares of the biopharmaceutical company’s stock worth $651,000 after acquiring an additional 62 shares during the period. Finally, Everhart Financial Group Inc. raised its position in Regeneron Pharmaceuticals by 14.8% during the second quarter. Everhart Financial Group Inc. now owns 550 shares of the biopharmaceutical company’s stock valued at $578,000 after acquiring an additional 71 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.